PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/00, 1/02, C12N 15/81, C12Q 1/68 | A1

(11) International Publication Number: WO 95/29254

(43) International Publication Date: 2 November 1995 (02.11.95)

(21) International Application Number: PCT/AU95/00235

(22) International Filing Date: 20 April 1995 (20.04.95)

(30) Priority Data:
PM 5169 20 April 1994 (20.04.94) AU

(71) Applicant *(for all designated States except US)*: GENE SHEARS PTY. LTD. [AU/AU]; Level 3, 154 Military Road, Neutral Bay, NSW 2089 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ATKINS, David [AU/AU]; 82 Womerah Avenue, Darlinghurst, NSW 2010 (AU). ARNDT, Gregory, Martin [CA/AU]; 6D/8 Hampden Street, Paddington, NSW 2021 (AU). IZANT, Jonathan, Goulder [US/AU]; 11 Byora Crescent, Northbridge, NSW 2063 (AU).

(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.

SG 9611643-9

(54) Title: AN *IN VIVO* GENE EXPRESSION SYSTEM

(57) Abstract

The present invention relates generally to an *in vivo* system for gene expression and, more particularly, to the use of the system to screen for molecules which are capable of inhibiting, reducing, altering or otherwise modulating the expression of a target nucleotide sequence or the activity of a gene product. The *in vivo* system of the present invention is particularly but not exclusively useful for screening for antisense, sense or ribozymes constructs or transdominant polypeptides, small peptides or other chemical compounds and which are capable of inhibiting, reducing, altering or otherwise modulating expression of target genes or target genetic sequences or the activity of target gene products of commercial importance such as in the medical, agricultural and industrial fields.

96 11 29